Evolving Concepts Regarding Selection of Patients for Cardiac Transplantation * Assessing Risks and Benefits

Chest

Volumn 109, Issue 1, 1996, Pages 223-232

  Torre Amione, Guillermo ^a   Kapadia, Samir ^a   Short III, David ^a   Young, James B ^b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEART FAILURE; HEART TRANSPLANTATION; HUMAN; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT PLANNING;

HEART FAILURE, CONGESTIVE; HEART TRANSPLANTATION; HUMANS; PATIENT SELECTION; PROGNOSIS; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL RATE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0030067939     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.109.1.223     Document Type: Review

References (63)

1. Garg R, Packer M, Pitt B, et al. Heart failure in the 1990s: evolution of a major public health problem in cardiovascular medicine. J Am Coll Cardiol 1993; 22(4 suppl A):3A-5A
2. O'Connell JB, Gunnar RM, Evans RG, et al. Organization of Heart transplantation in the US. J Am Coll Cardiol 1993;22:8-14
3. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: cardiac transplantation: task force 3: recipient guidelines/prioritization. J Am Coll Cardiol 1993; 22:21-31
4. Young JB, Naftel DC, Bourge RC, et al. Matching the heart donor and heart transplant recipient: clues for successful expansion of the donor pool: a multivariable, multiinstitutional report: the Cardiac Transplant Research Database Group. J Heart Lung Transplant 1994; 13:353-65
5. Young JB, Winters WL Jr, Bourge R, et al. 24th Bethesda conference: cardiac transplantation: task force 4: function of the heart transplant recipient. J Am Coll Cardiol 1993; 22:31-41
6. Evans RW, Manninen DL, Garrison LP Jr, et al. Donor availability as the primary determinant of the future of heart transplantation. JAMA 1986; 255:1892-98
7. O'Connell JB, Bourge RC, Costanzo-Nordin MR, et al. Cardiac transplantation: recipient selection, donor procurement, and medical follow-up: a statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1992; 86:1061-79
8. Hosenpud JD, Novick RJ, Breen TJ, et al. The Registry of the International Society for Heart and Lung Transplantation: 11th official report - 1994. J Heart Lung Transplant 1994; 13:561-70
9. Baker WB, Klein MS, Reardon MJ, et al. Reversible cardiac dysfunction (hibernation) from ischemia due to compression of the coronary arteries by a pseudoaneurysm. N Engl J Med 1991; 325:1858-61
10. Francis GS. Determinants of prognosis in patients with heart failure. J Heart Lung Transplant 1994; 13:S113-S16
11. Anguita M, Ariz'on JM, Bueno G, et al. Spontaneous clinical and hemodynamic improvement in patients on waiting list for heart transplantation. Chest 1992; 102:96-9
12. Garg R, Yusuf S. Current and ongoing randomized trials in heart failure and left ventricular dysfunction. J Am Coll Cardiol 1993; 22(4 suppl A):194A-97A
13. Afridi I, Kleiman NS, Raizner AE, et al. Dobutamine echocardiography in myocardial hibernation: optimal dose and accuracy in predicting recovery of ventricular function after coronary angioplasty. Circulation 1995; 91:663-70
14. Panza JA, Dilsizian V, Laurienzo JM, et al. Relation between thallium uptake and contractile response to dobutamine: implications regarding myocardial viability in patients with chronic coronary artery disease and left ventricular dysfunction. Circulation 1995; 91:990-98
15. Steimle AE, Stevenson LW, Fonarow GC, et al. Prediction of improvement in recent onset cardiomyopathy after referral for heart transplantation. J Am Coll Cardiol 1994; 23:553-59
16. Bourge RC, Naftel DC, Costanzo-Nordin MR, et al. Pretransplantation risk factors for death after heart transplantation: a multiinstitutional study: the Transplant Cardiologists Research Database Group. J Heart Lung Transplant 1993; 12:549-62
17. Kubo SH, Ormaza SM, Francis GS, et al. Trends in patient selection for heart transplantation. J Am Coll Cardiol 1993; 21:975-81
18. Anguita M, Ariz'on JM, Vall'es F, et al. Influence of heart transplantation on the natural history of patients with severe congestive heart failure. J Heart Lung Transplant 1993; 12(6, pt 1):974-82
19. Stevenson LW. Selection and management of patients for cardiac transplantation. Curr Opin Cardiol 1994; 9:315-25
20. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316:1429-35
21. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302
22. The SOLVD investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions [published erratum appears in N Engl J Med 1992; 327:1768]. N Engl J Med 1992; 327:685-91
23. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986; 73:257-67
24. Cohn JN, Johnson GR, Shabetai R, et al. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure: the V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(suppl):V15-V6
25. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II: the V-HeFT VA Cooperative Studies Group. Circulation 1993; 87(suppl):V140-V48
26. Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction: SOLVD investigators. J Am Coll Cardiol 1994; 23:1410-20
27. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-41
28. Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92:2303-12
29. Kapadia S, Torre-Amione G, Lee J, et al. Tumor necrosis factor alpha gene and protein expression in adult feline myocardium following endotoxin administration. J Clin Invest 1995; 96:1042-52
30. Torre-Amione G, Kapadia S, Lee J, et al. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92:1487-93
31. Feldman AM, Bristow MR, Parmley WW, et al. Effects of vesnarinone on morbidity and mortality in patients with heart failure: vesnarinone study group. N Engl J Med 1993; 329:149-55
32. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991; 83:778-86
33. Bittner V, Weiner D, Yusuf S, et al. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. JAMA 1993; 270:1702-07
34. LeJemtel TH, Liang CS, Stewart DK, et al. Reduced peak aerobic capacity in asymptomatic left ventricular systolic dysfunction: a substudy of the studies of left ventricular dysfunction (SOLVD): SOLVD investigator: studies of left ventricular dysfunction. Circulation 1994; 90:2757-60
35. Griepp RB, Stinson EB, Dong E Jr, et al. Determinants of operative risk in human heart transplantation. Am J Surg 1971; 122:192-97
36. Kirklin JK, Naftel DC, McGiffin DC, et al. Analysis of morbid events and risk factors for death after cardiac transplantation. J Am Coll Cardiol 1988; 11:917-24
37. Costard-Jackle A, Fowler MB. Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992; 19:48-54
38. Kirklin JK, Naftel DC, Kirklin JW, et al. Pulmonary vascular resistance and the risk of heart transplantation. J Heart Transplant 1988; 7:331-36
39. Erickson KW, Costanzo-Nordin MR, O'Sullivan EJ, et al. Influence of preoperative transpulmonary gradient on late mortality after orthotopic heart transplantation. J Heart Transplant 1990; 9:526-37
40. Young JB, Smart FW, Farmer JA, et al, eds. Coronary heart disease and risk factors: when to think of cardiac transplantation: heart replacement for terminal cardiac disease. New York: Futura Publishing, 1991; 295-313
41. Stevenson LW, Warner SL, Steimle AE, et al. The impending crisis awaiting cardiac transplantation: modeling a solution based on selection. Circulation 1994; 89:450-57
42. Stevenson LW, Fowler MB, Schroeder JS, et al. Poor survival of patients with idiopathic cardiomyopathy considered too well for transplantation. Am J Med 1987; 83:871-76
43. Kelly RA, Smith TW. Digoxin in heart failure: implications of recent trials. J Am Coll Cardiol 1993; 22(4, suppl A):107A-12A
44. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors: RADIANCE study. N Engl J Med 1993; 329:1-7
45. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial: PROVED investigative group. J Am Coll Cardiol 1993; 22:955-62
46. Grinstead WC, Francis MJ, Marks GF, et al. Discontinuation of chronic diuretic therapy in stable congestive heart failure secondary to coronary artery disease or to idiopathic dilated cardiomyopathy. Am J Cardiol 1994; 73:881-86
47. Cody RJ. Clinical trials of diuretic therapy in heart failure: research directions and clinical considerations. J Am Coll Cardiol 1993; 22:165A-71A
48. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE study research group. N Engl J Med 1991;325:1468-75
49. Gilbert EM, Packer M. The use of placebo controls [letter]. N Engl J Med 1995; 332:61-2
50. Haynes WG, Webb DJ. Flosequinan in heart failure [letter; comment]. Lancet 1993; 341:1100-01
51. Eichhorn EJ, Heesch CM, Barnett JH, et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994; 24:1310-20
52. Beta-Blocker Heart Attack Study Group. The beta-blocker heart attack trial. JAMA 1981; 246:2073-74
53. The Study Group. A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 1982; 247:1707-14
54. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy: metoprolol in dilated cardiomyopathy (MDC) trial study group. Lancet 1993; 342:1441-46
55. Feldman AM, Baughman KL, Lee WK, et al. Usefulness of OPC-8212, a quinolinone derivative, for chronic congestive heart failure in patients with ischemic heart disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68:1203-10
56. Young JB, Weiner DH, Yusuf S, et al. Patterns of medication use in patients with heart failure: a report from the registry of Studies of Left Ventricular Dysfunction (SOLVD). South Med J 1995; 88:514-23
57. Cohn JN. The prevention of heart failure - a new agenda [editorial] [published erratum appears in N Engl J Med 1992; 327:1184]. N Engl J Med 1992; 327:725-27
58. Pfeffer MA, Braunwald E, Moy'e La, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial: the SAVE investigators. N Engl J Med 1992; 327:669-77
59. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325:303-10
60. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314:1547-52
61. Mann DL, Urabe Y, Kent RL, et al. Cellular versus myocardial basis for the contractile dysfunction of hypertrophied myocardium. Circ Res 1991; 68:402-15
62. Mann DL, Kent RL, Cooper G IV. Load regulation of the properties of adult feline cardiocytes: growth induction by cellular deformation. Circ Res 1989; 64:1079-90
63. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90:1765-73